Pear Therapeutics is looking to enter the depression space with the acquisition of fellow digital-therapeutic company Waypoint Health Innovations’ assets, as well as the assets of Örebro University researcher Fredrik Holländare.
“The addition of these depression assets to our portfolio fits squarely in our near-term focus to expand our leadership in psychiatry. With these deals, we have the...
Prescription digital therapeutics company Pear Therapeutics began trading on Nasdaq Monday after wrapping up its merger with special-purpose acquisition company Thimble Point Acquisition Corp. last week.
The business combination brought in about $175 million, which the company said will be used to capitalize its digital therapeutic products. It's trading under the ticker symbol PEAR.
"My...
Pear Therapeutics announced Monday it had received Breakthrough Device Designation from the FDA for its prescription digital therapeutic aimed at treating alcohol use disorder, reSET-A.
The news comes just ahead of the company’s planned merger with a special purpose acquisition company, Thimble Point Acquisition Corp., which will allow it to trade publicly. Pear already has FDA-cleared digital...
Digital prescription therapeutic company Pear Therapeutics announced Monday it had secured up to $50 million in additional capital from an affiliate of Thimble Point Acquisition Corp., the special purpose acquisition company it plans to merge with in order to trade publicly.
The new investment is adding to the $23 million Thimble Point’s sponsor already committed as part of the private investment...
Pear Therapeutics announced Wednesday that Massachusetts’ Medicaid program plans to cover its digital prescription therapeutics for treating substance and opioid use disorders, reSET and reSET-O.
The decision to cover the digital therapeutics under MassHealth is subject to federal and state approval as well as the availability of funding.
“We applaud MassHealth for their leadership in introducing...
A "refill" of Pear Therapeutics’ reSET-O digital prescription therapeutic for treating opioid use disorder is associated with high levels of abstinence and treatment retention as well as fewer hospital encounters, according to a study published in Hospital Practice.
Most of the study’s authors are current or former Pear employees.
TOP-LINE DATA
Out of a group of 3,817 people who completed a 12-...
Pear Therapeutics’ reSET-O prescription digital therapeutic for opioid use disorder lowered healthcare costs and added quality life years post-treatment, according to a Pear-funded analysis published in the Journal of Market Access & Health Policy.
TOP-LINE DATA
Over 12 weeks, using reSET-O in addition to treatment as usual lowered costs by $1,014 and added 0.003 quality-adjusted life years...
Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in the journal Hospital Practice.
“Engagement and continued treatment with reSET-O in patients with OUD treated with buprenorphine is associated with substantial real-world reductions in medical costs...
Digital therapeutic company Pear announced its plans to go public via a $1.6 billion special purpose acquisition company (SPAC) merger with Thimble Point Acquisition Corp.
The new combined company will be called Pear Holdings Corp and traded on Nasdaq. Pear leadership will continue to head up the new combined entity. According to the companies, the combined business includes up to $276 million in...
Digital therapeutics company Pear Therapeutics is looking to integrate digital biomarkers, machine learning algorithms and sensor-based technologies into its platform thanks to new licensing deals and partnerships.
The Boston-based DTx company has inked collaboration deals with Empatica and etectRx, as well as licensing tech from KeyWise.
Specifically, Pear's collaboration with Empatica will...